人肝癌p57~（kip2）遗传不稳定性与mRNA和蛋白表达关系研究
|
摘要
目的:研究P57~(kip2)基因在人肝细胞癌(Hepatocellular carcinoma,HCC)不同阶段的杂合性缺失(Loss of heterozygosity,LOH)、微卫星不稳定性(Microsatellite instability,MSI)及其mRNA和蛋白表达情况,以及它们之间的相互关系,以探讨HCC发生的分子生物学机制。
方法:运用PCR—聚丙烯酰胺凝胶电泳—银染法对30例肝癌组织及其癌周肝硬化组织P57~(kip2)基因所在染色体区域的3个微卫星位点(D11S1760,D11S922和D11S1338)进行LOH和MSI检测,同时运用原位分子杂交和免疫组化技术分别检测30例正常肝组织、30例癌周肝硬化组织和30例肝癌组织中P57~(kip2)mRNA及P57~(kip2)蛋白的表达情况。
结果:1.LOH及MSI检测:30例肝癌组织中3个位点均未发生LOH:在2个微卫星位点发生MSI,MSI总阳性率为16.7%。
2.P57~(kip2)mRNA表达:正常肝组织未见表达,癌周肝硬化组与肝癌组阳性表达率均为26.7%(8/30)。肝癌组高分化、中分化和低分化三组之间P57~(kip2)mRNA表达差异有统计学意义。
3.P57~(kip2)蛋白表达:正常肝组织未见表达,癌周肝硬化组与肝癌组阳性表达率均为56.67%(17/30)。肝癌组高分化、中分化和低分化三组之间P57~(kip2)蛋白表达差异有统计学意义。
4.肝癌组微卫星位点D11S1760发生MSI与P57~(kip2)mRNA和蛋白表达均有关联性。
5.肝癌组P57~(kip2)mRNA与蛋白表达之间有关联性。
结论:1.P57~(kip2)mRNA和蛋白表达异常提示其可能在HCC发生过程中起重要作用。
2.与P57~(kip2)基因同一区域的3个微卫星位点均未发生LOH,提示这3个位点不是P57~(kip2)基因LOH的频发位点,与P57~(kip2)mRNA和蛋白表达异常无关。
3.P57~(kip2)基因同一区域的2个微卫星位点发生MSI,同时伴有P57~(kip2)mRNA和蛋白表达异常,提示MSI可能是肝癌发生过程中P57~(kip2)mRNA和蛋白表达异常的原因之一。
4.微卫星位点D11S1760发生MSI与P57~(kip2)mRNA和蛋白表达异常有关联,提示该位点可能是肝癌P57~(kip2)表达异常的特异性标志位点。
Objective:To study the loss of hererozygosity(LOH)and microsatellite instability(MSI)of P57~(kip2)and expressions of P57~(kip2)mRNA & protein in human hepatocellular carcinoma(HCC)in order to explore the molecular mechanism of hepatocarcinogenesis.
Methods:MSI and LOH of three microsatellite locis (D11S1760,D11S922and D11S1338)were detected where the P57~(kip2)gene is in by using PCR-Polyacrylamide gel electrophoresis-silver staining method in 30 cases of HCC.Immunohistochemistry staining and in situ hybridization(ISH)were also used to show the expression of P57~(kip2) protein and mRNA in pericancerous cirrhosis and HCC.
Results:1.LOH and MSI detected:LOH was not identified in 30 cases on three microsatellite locies;there were 2 microsatellite locies showing MSI,the total rate of MSI was 16.7%
2.Expression of P57~(kip2)mRNA:There were no expressions in normal liver tissue.Expressions both in pericancerous cirrhosis and hepatocellular carcinoma was 26.67%(8/30).There was significant difference between the expressions in high differentiated HCC tissues,moderately differentiated HCC tissues and low differentiated HCC tissues.
3.Expression of P57~(kip2)protein:There were no expressions in normal liver tissue.Expressions in precancerous cirrhosis and hepatocellular carcinoma was 56.67%(17/30)respectively.There was no significant difference between the expressions in high differentiated HCC tissues, moderately differentiated HCC tissues and low differentiated HCC tissues.
4.There was correlation between the MSI of D11S1760 locies and the expression of P57~(kip2)mRNA;there was correlation between the MSI of D11S1760 locies and the expression of P57~(kip2)protein.
5.There was positive correlation between expression of P57~(kip2)mRNA and expression of P57~(kip2)protein.
Conclusion:1.The disorder expressions of P57~(kip2)mRNA and protein indicated that P57~(kip2)may be involved in hepatocarcinogenesis and prognosis.
2.LOH was not identified on three microsatellite locies,which indicated that there may be another reason for the disorder expression of P57~(kiP2).
3.Two microsatellite locis showed MSI where the P57~(kip2)gene is in, with the disorder expression of P57~(kip2)mRNA and protein,indicated that MSI may be one of the reasons that lead to the disorder expression of P57~(kip2)mRNA and protein in hepatocarcinogenesis and prognosis.
4.There was correlation between the MSI of D11S1760 locies and the expression of P57~(kip2)mRNA and protein,which indicated that MSI of D11S1760 may the specifical marker for the disorder expression of P57~(kip2)in HCC.
方法:运用PCR—聚丙烯酰胺凝胶电泳—银染法对30例肝癌组织及其癌周肝硬化组织P57~(kip2)基因所在染色体区域的3个微卫星位点(D11S1760,D11S922和D11S1338)进行LOH和MSI检测,同时运用原位分子杂交和免疫组化技术分别检测30例正常肝组织、30例癌周肝硬化组织和30例肝癌组织中P57~(kip2)mRNA及P57~(kip2)蛋白的表达情况。
结果:1.LOH及MSI检测:30例肝癌组织中3个位点均未发生LOH:在2个微卫星位点发生MSI,MSI总阳性率为16.7%。
2.P57~(kip2)mRNA表达:正常肝组织未见表达,癌周肝硬化组与肝癌组阳性表达率均为26.7%(8/30)。肝癌组高分化、中分化和低分化三组之间P57~(kip2)mRNA表达差异有统计学意义。
3.P57~(kip2)蛋白表达:正常肝组织未见表达,癌周肝硬化组与肝癌组阳性表达率均为56.67%(17/30)。肝癌组高分化、中分化和低分化三组之间P57~(kip2)蛋白表达差异有统计学意义。
4.肝癌组微卫星位点D11S1760发生MSI与P57~(kip2)mRNA和蛋白表达均有关联性。
5.肝癌组P57~(kip2)mRNA与蛋白表达之间有关联性。
结论:1.P57~(kip2)mRNA和蛋白表达异常提示其可能在HCC发生过程中起重要作用。
2.与P57~(kip2)基因同一区域的3个微卫星位点均未发生LOH,提示这3个位点不是P57~(kip2)基因LOH的频发位点,与P57~(kip2)mRNA和蛋白表达异常无关。
3.P57~(kip2)基因同一区域的2个微卫星位点发生MSI,同时伴有P57~(kip2)mRNA和蛋白表达异常,提示MSI可能是肝癌发生过程中P57~(kip2)mRNA和蛋白表达异常的原因之一。
4.微卫星位点D11S1760发生MSI与P57~(kip2)mRNA和蛋白表达异常有关联,提示该位点可能是肝癌P57~(kip2)表达异常的特异性标志位点。
Objective:To study the loss of hererozygosity(LOH)and microsatellite instability(MSI)of P57~(kip2)and expressions of P57~(kip2)mRNA & protein in human hepatocellular carcinoma(HCC)in order to explore the molecular mechanism of hepatocarcinogenesis.
Methods:MSI and LOH of three microsatellite locis (D11S1760,D11S922and D11S1338)were detected where the P57~(kip2)gene is in by using PCR-Polyacrylamide gel electrophoresis-silver staining method in 30 cases of HCC.Immunohistochemistry staining and in situ hybridization(ISH)were also used to show the expression of P57~(kip2) protein and mRNA in pericancerous cirrhosis and HCC.
Results:1.LOH and MSI detected:LOH was not identified in 30 cases on three microsatellite locies;there were 2 microsatellite locies showing MSI,the total rate of MSI was 16.7%
2.Expression of P57~(kip2)mRNA:There were no expressions in normal liver tissue.Expressions both in pericancerous cirrhosis and hepatocellular carcinoma was 26.67%(8/30).There was significant difference between the expressions in high differentiated HCC tissues,moderately differentiated HCC tissues and low differentiated HCC tissues.
3.Expression of P57~(kip2)protein:There were no expressions in normal liver tissue.Expressions in precancerous cirrhosis and hepatocellular carcinoma was 56.67%(17/30)respectively.There was no significant difference between the expressions in high differentiated HCC tissues, moderately differentiated HCC tissues and low differentiated HCC tissues.
4.There was correlation between the MSI of D11S1760 locies and the expression of P57~(kip2)mRNA;there was correlation between the MSI of D11S1760 locies and the expression of P57~(kip2)protein.
5.There was positive correlation between expression of P57~(kip2)mRNA and expression of P57~(kip2)protein.
Conclusion:1.The disorder expressions of P57~(kip2)mRNA and protein indicated that P57~(kip2)may be involved in hepatocarcinogenesis and prognosis.
2.LOH was not identified on three microsatellite locies,which indicated that there may be another reason for the disorder expression of P57~(kiP2).
3.Two microsatellite locis showed MSI where the P57~(kip2)gene is in, with the disorder expression of P57~(kip2)mRNA and protein,indicated that MSI may be one of the reasons that lead to the disorder expression of P57~(kip2)mRNA and protein in hepatocarcinogenesis and prognosis.
4.There was correlation between the MSI of D11S1760 locies and the expression of P57~(kip2)mRNA and protein,which indicated that MSI of D11S1760 may the specifical marker for the disorder expression of P57~(kip2)in HCC.
引文
[1]Parkin Dm,Bray F,Ferlyay J,et al.Global Cancer statistics,2002[J].CA Cancer Clin,2005,55(2):74.
[2]从文铭.肿瘤抑制基因变异的分子病理学研究进展[J].中华病理志,2001,30(1):58-60.
[3]Lobe LA.A mutator phenotype in cancer[J].Cancer Res,2001,61(8):3230-3239.
[4]周尊强,赵金鹏.微卫星不稳定性与恶性肿瘤[J].国际遗传学杂志,2006,15(19):74-76.
[5]刘彤华.诊断病理学[M].北京.人民卫生出版社,2006:566-571.
[6]Halford SE,Sawyer EJ,Lambros MB,et al.MSI21ow,a real phenomenon which varies in frequency among cancer types[J].J Pathol,2003,201:3892394.
[7]Kawamata N,Morosetti R,Miller CW,et al.Molecular analysis of the cyclin-dependent kinase inhibitor gene p27~(kipl)in human malignancies[J].Cancer Res,1995,55(11):2266-2269.
[8]Russo AA,Jeffrey PD,Patten AK,et al.Crystal structure of the p27~(kipl)cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex[J].Nature,1996,382(6589):325-331.
[9]Luo Y,Hurwitz J,Massagen J,et al.Cell-cyclin inhibition by independent CDK and PCNA binding domains in p21~(Cipl)[J].Nature,1995,375(6527):159-161.
[10]Reid LH,Crider Miller SJ,Ande West,et al.Genomic organization of the human p57~(kip2)gene and its analysis in the G401 Wilms' Tumor assay[J].Cancer Res,1996,56(6):1214-1218.
[11]Rosenberg E,Demopoulos RI,Jacquotte AZ,et al.Expression of cell cycle regulation regulators p57~(kip2),CyclinD_1 and CyclinE in epithelial ovarian tumors and survival[J].Hum Pathol 2001;32:808-813.
[12]Zhang PM,Liegeosis NJ,Wong C,et al.Altered cell differentiation and proliferation in mice lacking p57~(kip2)indicates a role in Beckwith-Wiedemann syndrome[J].Nature,1997,387:151.
[13]曹守强等.p57~(kip2)蛋白在进展期胃癌中的表达及临床意义[J].哈尔滨医科大学学报,2004,(6):561-563.
[14]Ito Y,takeda T,Wakasa k,et al.Expression of p57~(kip2)protein in pancreatic adenocarcinoma[J].Pancreas,2001,23(3):246-256.
[15]Noura S,Yamamoto H,Sekimoto M,et al.Expression of second class of KIP protein p57~(kip2)in human colorectal carcinoma[J].Int J Oncol,2001,1991(1):39-47.
[16]郭伟平,王泽华.p57~(kip2)和cyclinE在人宫颈癌中的表达及其与临床病理及预后的关系[J].第四军医大学学报,2006,27(15):1434-1437.
[17]Dyer MA,Cepko CL.P57(Kip2)regulates progenitor cell proliferation and amacrine interneuron development in the mouse retina[J].Development,2000,Aug;127(16):3593-605.
[18]Hoffmann MJ,Florl AR,Seifert HH,et al.Multiple mechanisms downregulate CDKN1C in human bladder cancer[J].Int J Cancer,2005 Apr 10;114(3):406-413.
[19]Hofer TP,Frankenberqer M,Staples KJ,et al.Expression of p57-Kip2 in monocytes and macrophages[J].Immunobiology,2006;211(6-8):455-62.
[20]Duquas JC,Ibrahim A,et al.A crucial role for p57(Kip2)in the intracellular timer that controls oligodendrocyte differentiation[J].2007 Jun 6;27(23):6185-96.
[21]Pateras IS,Apostolopoulou K,Koutsami M,et al.Downregulation of the KIP family members p27(KIP1)and p57(KIP2)by SKP2 and the role of methylation in p57(KIP2)inactivation in nonsmall cell lung cancer[J].Int J Cancer,2006Dec 1;119(11):2546-56.
[22]Lianq B,Wanq S,Yanq X,et al.Expressions of cyclin E,cyclin dependent kinase2and p57(KIP2)inhumangastriccancer[J].ChinMedJ(Enql),2003Jan;116(1):20-3.
[23]Li JQ,Wu F,Usuki H,et al.Loss of p57~(KIP2)is associated with colorectal carcinogenesis[J].Int J Oncol,2003 Dec;23(6):1537-43.
[24]Fan GK,Chen J,Pinq F,et al.Immunohistochemical analysis of P57(kip2),p53and hsp60 expressions in premalignant and malignant oral tissues[J].Oral Oncol,2006 Feb;42(2):147-53.
[25]Lai S,Goepfert H,et al.Loss of imprinting and genetic alterations of the cyclin-dependent kinase inhibitor p57KIP2 gene in head and neck squamous cell carcinoma[J].Clin Cancer Res,2000 Aug;6(8):3172-6.
[26]姚卫东,姜惠峰,曲桂梅等.肝细胞癌组织中endoglin(CD105)和VEGF及p57~(kip2)表达与预后的关系[J].肿瘤防治杂志,2005,March,Vol.12 No.5.
[27]邹琼等.人类肝癌发生过程中CyclinD_1和CDK_4及P16蛋白的表达[J].肿瘤防治杂志,2005,12(15):1127-1131.
[28]孔萌萌.Rb与p57~(kip2)在肝细胞癌发生发展过程中的表达研究:[硕士学位论文]。昆明医学院:基础医学院,2004.
[29]周峥珍.DEN诱发大鼠肝癌的病理学及细胞周期调控因子表达的研究:[硕士学位论文]。昆明医学院:基础医学院,2005.
[30]郭卉等.p57~(kip2)在肝癌组织中的表达及其于临床病理因素、PCNA和P53的关系[J].第 四军医大学学报,2004,25(17):1562-1565.
[31]Nakai S,Maszki T,Shiratori Y,et al.Expression of p57~(kip2)in hepatocellular carcinoma:relationship between tumor differentiation and patient survival[J].Int Oncol,2002,20(4):769-775.
[32]Nan KJ,Guo H,Ruan ZP,et al.Expression of p57(kip2)and its relationship with clinicopathology,PCNA and p53 in primary hepatocellular carcinoma[J].Clin Cancer Res,2005,20(16):346-350.
[33]Overall ML,Spencer J,Bakker M,et al.p57~(KIP2)is expressed in Wilms' tumor with LOH of 11p15.5[J].Genes Chromosomes Cancer,1996 Sep;17(1):56-9.
[34]Christine Sempoux,Yves Guiot,Karin Dahan,et al.The focal form of persistent hyperinsulinemic hypoglycemia of infancy[J].Diabetes,52:784-794,2003.
[35]Syeling Lai,Helmuth Goepfert,Ann M.Gillenwater,et al.Loss of Imprinting and Genetic Alterations of the Cyclin-dependent Kinase Inhibitor p57~(KIP2)Gene in Head and Neck Squamous Cell Carcinoma[J].Clinical Cancer Research,2000,6(8),3172-3176.
[36]Macdonald GA,Green son TK,Ssitok,et al.Microsatellite instability ad loss of hetero zygosity at DNA mismatch repair gene loci occurs during hepatic carcinogenesis[J].Hepatology,199828(1):90-97.
[37]Wang G,Zhao Y,Liu X,et al.Allelic loss and gain,but not genomic instability,as the major somatic mutation in primary hepatocellular carcinoma[J].Genes Chromosomes Cancer,2001,31:2212227.
[38]丛文铭,张树辉,冼志红等.肝细胞癌肿瘤抑制基因的杂合性缺失和微卫星不稳定性研究[J].中华病理学杂志,2005,34:71-74.
[1]从文铭.肿瘤抑制基因变异的分子病理学研究进展[J].中华病理学杂志,2001,30(1):58-60.
[2]Lobe LA.A mutator phenotype in cancer[J].Cancer Res,2001,61(8):3230-3239.
[3]张建军,安倩,高燕宁,等.微卫星与肿瘤[J].癌症,200,10(6):45-47.
[4]周尊强,赵金鹏.微卫星不稳定性与恶性肿瘤[J].国际遗传学杂志,2006,15(19):74-76.
[5]Muller A,Fishel R.Mismatch repair and the hereditary non-polyposis colorectal cancer syndrome[J].Cancer Invest,2002,20(1):102-9.
[6]Muta H,Noguchi M,Perucho M,et al.Chinical implications of microsatellite instability in colorectal cancers[J].Cancer,1996,77(2):265-70.
[7]Narayan S,Roy D.Role of APC and DNA mismatch repair genes in the development of colorectal cancers[J].Mol Cancer,2003,2(1):41.
[8]Garcia JM,Rodriguez R,Dominguez G,et al.Prognostic significance of the allelic loss of the BRAC1 gene incolorectalcancer[J].Gut,2003,52(12):1756-1763.
[9]Brenner BM,Stoler DL,Rodriguez L,et al.Allelic losses at genomic instability-associated loci in villous adenomas and adjacent colorectal cancers[J].Cancer Genet Cytogenet,2007,174(1):9-15.
[10]郑海涛,彭志海.周崇治,等.散发性结直肠癌D10S1256位点的杂合性缺失分析[J].中国肿瘤临床,2005,32(3):121-124.
[11]周崇治,裘国强,张放,等.83例散发性结直肠癌D22S274位点杂合性缺失分析[J].肿瘤,2004,24(1):18-20.
[12] Fang DC, Lou YH, Yang SM, et al. Mutation analysis of APC gene in gastric cancer with microsatellite instability [J]. World J Gastroenterol, 2002, 8(5):787-91.
[13] Vauhkonen H , Hedman M, Vauhkonen M, et al. Evaluation of gastrointestinal cancer tissues as a source of genetic information for forensic investigations by using STRs[J]. Forensic Sci Int. 2004,139(2-3):159-67.
[14] Xiao YP,Wu DY, Xu L, et al. Loss of heterozygosity and microsatellite instabilities of fragile histidine triad gene in gastric carcinoma[J]. World J Gastroenterol, 2006,12(23):3766-9.
[15] Oki E, kakeji Y, Baba H, et al. Impact of loss of heterozygosity of encodingphosphate and tensin homolog on the prognosis of gastric cancer[J].J Gastroentreol Hepatol , 2006,21(5):814-8.
[16] Maggioni M ,Coggi G, Cassani B , et al. Molecular changes in hepatocellular dysplastic nodules on microdissected liver biopsies [J].Hepatology , 2000, 32 (5): 942 - 946.
[17] Guang-Neng Zhu, Li Zuo, Qing Zhou, et al.Loss of heterozygosity on chromosome 10q22-10q23 and 22q11.2-22q12.1 and p53 gene in primary hepatocellular carcinoma[J]. World J Gastroenterol, 2004,10(13):1975-1978.
[18] Tomoe Lu, Hiroshi Hano, Chenxi Meng ,et al. Frequent loss of heterozygosity in two distinct regions , 8p23.1 and 8p22, in hepatocellular carcinoma[J]. World J Gastroenterol, 2007,13 (7):1090-1097.
[19] Wani K,Nair CK. Genetic alterations in cervical cancer[J]. Indian J Exp Biol,2003, 41(8):789-96.
[20] Chung TK, Cheung TH, Lo WK, et al.Loss of heterozygosity at the short arm of chromosome 3 in microdissected cervical intraepithelial neoplasia[J]. CancerLett, 2000,154 (2): 189-94.
[21] Kanianaviroikul N, Kohu K, Sato M, et al. Candidate regions of tumor suppressor gene by loss of heterozygosity analysis on chromosome 8pll. l-ql3. 3 in gastric cancer[J]. Cancer Lett, 2004,213(1):111-6.
[22] Caldes T, Perez-Sequra P, Torar A, et al. Microsatellite instability correlates with negative expression of estrogen and progesterone receptors in sporadic breast cancer[J]. Teratog Carcinog Mutagen, 2000,20(5):283-91.
[23] Nowacka-Zawisza M,Brys M, Hanna RM,et al .Loss of heterozygosity and microsatellite instability at RAD52 and RAD54 loci in breast cancer[J].Pol J Pathol, 2006;57 (2):83-9.
[24] Wistuba, II.Behrens C, Virmani AK:High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints[J]. Cancer Res, 2000,60:1949-1960.
[25] Eva FORGACS, Sabine ZOCHBAUER-MOLLER, Edit OLAH, et al. Molecular Genetic Abnormalities in the Pathogenesis of Human Lung Cancer[J]. Pathology oncology research, 2001,7 (1): 7-13.
[26] Takeuchi T, Minami Y, Iijima T, et al. Characteristics of loss of heterozygosity in large cell neuroendocrine carcinomas of the lung and small cell lung carcinomas[J]. Pathol Int,2006 56(8):434-9.
[27] Ninomiva H, Nomura K, Satoh Y, et al. Genetic instability in lung cancer: concurrent analysis of chromosomal,mini-and microsatellite instability and loss of heterozygosity[J].Br J Cancer, 2006, 94(10):1485-91.
[2]从文铭.肿瘤抑制基因变异的分子病理学研究进展[J].中华病理志,2001,30(1):58-60.
[3]Lobe LA.A mutator phenotype in cancer[J].Cancer Res,2001,61(8):3230-3239.
[4]周尊强,赵金鹏.微卫星不稳定性与恶性肿瘤[J].国际遗传学杂志,2006,15(19):74-76.
[5]刘彤华.诊断病理学[M].北京.人民卫生出版社,2006:566-571.
[6]Halford SE,Sawyer EJ,Lambros MB,et al.MSI21ow,a real phenomenon which varies in frequency among cancer types[J].J Pathol,2003,201:3892394.
[7]Kawamata N,Morosetti R,Miller CW,et al.Molecular analysis of the cyclin-dependent kinase inhibitor gene p27~(kipl)in human malignancies[J].Cancer Res,1995,55(11):2266-2269.
[8]Russo AA,Jeffrey PD,Patten AK,et al.Crystal structure of the p27~(kipl)cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex[J].Nature,1996,382(6589):325-331.
[9]Luo Y,Hurwitz J,Massagen J,et al.Cell-cyclin inhibition by independent CDK and PCNA binding domains in p21~(Cipl)[J].Nature,1995,375(6527):159-161.
[10]Reid LH,Crider Miller SJ,Ande West,et al.Genomic organization of the human p57~(kip2)gene and its analysis in the G401 Wilms' Tumor assay[J].Cancer Res,1996,56(6):1214-1218.
[11]Rosenberg E,Demopoulos RI,Jacquotte AZ,et al.Expression of cell cycle regulation regulators p57~(kip2),CyclinD_1 and CyclinE in epithelial ovarian tumors and survival[J].Hum Pathol 2001;32:808-813.
[12]Zhang PM,Liegeosis NJ,Wong C,et al.Altered cell differentiation and proliferation in mice lacking p57~(kip2)indicates a role in Beckwith-Wiedemann syndrome[J].Nature,1997,387:151.
[13]曹守强等.p57~(kip2)蛋白在进展期胃癌中的表达及临床意义[J].哈尔滨医科大学学报,2004,(6):561-563.
[14]Ito Y,takeda T,Wakasa k,et al.Expression of p57~(kip2)protein in pancreatic adenocarcinoma[J].Pancreas,2001,23(3):246-256.
[15]Noura S,Yamamoto H,Sekimoto M,et al.Expression of second class of KIP protein p57~(kip2)in human colorectal carcinoma[J].Int J Oncol,2001,1991(1):39-47.
[16]郭伟平,王泽华.p57~(kip2)和cyclinE在人宫颈癌中的表达及其与临床病理及预后的关系[J].第四军医大学学报,2006,27(15):1434-1437.
[17]Dyer MA,Cepko CL.P57(Kip2)regulates progenitor cell proliferation and amacrine interneuron development in the mouse retina[J].Development,2000,Aug;127(16):3593-605.
[18]Hoffmann MJ,Florl AR,Seifert HH,et al.Multiple mechanisms downregulate CDKN1C in human bladder cancer[J].Int J Cancer,2005 Apr 10;114(3):406-413.
[19]Hofer TP,Frankenberqer M,Staples KJ,et al.Expression of p57-Kip2 in monocytes and macrophages[J].Immunobiology,2006;211(6-8):455-62.
[20]Duquas JC,Ibrahim A,et al.A crucial role for p57(Kip2)in the intracellular timer that controls oligodendrocyte differentiation[J].2007 Jun 6;27(23):6185-96.
[21]Pateras IS,Apostolopoulou K,Koutsami M,et al.Downregulation of the KIP family members p27(KIP1)and p57(KIP2)by SKP2 and the role of methylation in p57(KIP2)inactivation in nonsmall cell lung cancer[J].Int J Cancer,2006Dec 1;119(11):2546-56.
[22]Lianq B,Wanq S,Yanq X,et al.Expressions of cyclin E,cyclin dependent kinase2and p57(KIP2)inhumangastriccancer[J].ChinMedJ(Enql),2003Jan;116(1):20-3.
[23]Li JQ,Wu F,Usuki H,et al.Loss of p57~(KIP2)is associated with colorectal carcinogenesis[J].Int J Oncol,2003 Dec;23(6):1537-43.
[24]Fan GK,Chen J,Pinq F,et al.Immunohistochemical analysis of P57(kip2),p53and hsp60 expressions in premalignant and malignant oral tissues[J].Oral Oncol,2006 Feb;42(2):147-53.
[25]Lai S,Goepfert H,et al.Loss of imprinting and genetic alterations of the cyclin-dependent kinase inhibitor p57KIP2 gene in head and neck squamous cell carcinoma[J].Clin Cancer Res,2000 Aug;6(8):3172-6.
[26]姚卫东,姜惠峰,曲桂梅等.肝细胞癌组织中endoglin(CD105)和VEGF及p57~(kip2)表达与预后的关系[J].肿瘤防治杂志,2005,March,Vol.12 No.5.
[27]邹琼等.人类肝癌发生过程中CyclinD_1和CDK_4及P16蛋白的表达[J].肿瘤防治杂志,2005,12(15):1127-1131.
[28]孔萌萌.Rb与p57~(kip2)在肝细胞癌发生发展过程中的表达研究:[硕士学位论文]。昆明医学院:基础医学院,2004.
[29]周峥珍.DEN诱发大鼠肝癌的病理学及细胞周期调控因子表达的研究:[硕士学位论文]。昆明医学院:基础医学院,2005.
[30]郭卉等.p57~(kip2)在肝癌组织中的表达及其于临床病理因素、PCNA和P53的关系[J].第 四军医大学学报,2004,25(17):1562-1565.
[31]Nakai S,Maszki T,Shiratori Y,et al.Expression of p57~(kip2)in hepatocellular carcinoma:relationship between tumor differentiation and patient survival[J].Int Oncol,2002,20(4):769-775.
[32]Nan KJ,Guo H,Ruan ZP,et al.Expression of p57(kip2)and its relationship with clinicopathology,PCNA and p53 in primary hepatocellular carcinoma[J].Clin Cancer Res,2005,20(16):346-350.
[33]Overall ML,Spencer J,Bakker M,et al.p57~(KIP2)is expressed in Wilms' tumor with LOH of 11p15.5[J].Genes Chromosomes Cancer,1996 Sep;17(1):56-9.
[34]Christine Sempoux,Yves Guiot,Karin Dahan,et al.The focal form of persistent hyperinsulinemic hypoglycemia of infancy[J].Diabetes,52:784-794,2003.
[35]Syeling Lai,Helmuth Goepfert,Ann M.Gillenwater,et al.Loss of Imprinting and Genetic Alterations of the Cyclin-dependent Kinase Inhibitor p57~(KIP2)Gene in Head and Neck Squamous Cell Carcinoma[J].Clinical Cancer Research,2000,6(8),3172-3176.
[36]Macdonald GA,Green son TK,Ssitok,et al.Microsatellite instability ad loss of hetero zygosity at DNA mismatch repair gene loci occurs during hepatic carcinogenesis[J].Hepatology,199828(1):90-97.
[37]Wang G,Zhao Y,Liu X,et al.Allelic loss and gain,but not genomic instability,as the major somatic mutation in primary hepatocellular carcinoma[J].Genes Chromosomes Cancer,2001,31:2212227.
[38]丛文铭,张树辉,冼志红等.肝细胞癌肿瘤抑制基因的杂合性缺失和微卫星不稳定性研究[J].中华病理学杂志,2005,34:71-74.
[1]从文铭.肿瘤抑制基因变异的分子病理学研究进展[J].中华病理学杂志,2001,30(1):58-60.
[2]Lobe LA.A mutator phenotype in cancer[J].Cancer Res,2001,61(8):3230-3239.
[3]张建军,安倩,高燕宁,等.微卫星与肿瘤[J].癌症,200,10(6):45-47.
[4]周尊强,赵金鹏.微卫星不稳定性与恶性肿瘤[J].国际遗传学杂志,2006,15(19):74-76.
[5]Muller A,Fishel R.Mismatch repair and the hereditary non-polyposis colorectal cancer syndrome[J].Cancer Invest,2002,20(1):102-9.
[6]Muta H,Noguchi M,Perucho M,et al.Chinical implications of microsatellite instability in colorectal cancers[J].Cancer,1996,77(2):265-70.
[7]Narayan S,Roy D.Role of APC and DNA mismatch repair genes in the development of colorectal cancers[J].Mol Cancer,2003,2(1):41.
[8]Garcia JM,Rodriguez R,Dominguez G,et al.Prognostic significance of the allelic loss of the BRAC1 gene incolorectalcancer[J].Gut,2003,52(12):1756-1763.
[9]Brenner BM,Stoler DL,Rodriguez L,et al.Allelic losses at genomic instability-associated loci in villous adenomas and adjacent colorectal cancers[J].Cancer Genet Cytogenet,2007,174(1):9-15.
[10]郑海涛,彭志海.周崇治,等.散发性结直肠癌D10S1256位点的杂合性缺失分析[J].中国肿瘤临床,2005,32(3):121-124.
[11]周崇治,裘国强,张放,等.83例散发性结直肠癌D22S274位点杂合性缺失分析[J].肿瘤,2004,24(1):18-20.
[12] Fang DC, Lou YH, Yang SM, et al. Mutation analysis of APC gene in gastric cancer with microsatellite instability [J]. World J Gastroenterol, 2002, 8(5):787-91.
[13] Vauhkonen H , Hedman M, Vauhkonen M, et al. Evaluation of gastrointestinal cancer tissues as a source of genetic information for forensic investigations by using STRs[J]. Forensic Sci Int. 2004,139(2-3):159-67.
[14] Xiao YP,Wu DY, Xu L, et al. Loss of heterozygosity and microsatellite instabilities of fragile histidine triad gene in gastric carcinoma[J]. World J Gastroenterol, 2006,12(23):3766-9.
[15] Oki E, kakeji Y, Baba H, et al. Impact of loss of heterozygosity of encodingphosphate and tensin homolog on the prognosis of gastric cancer[J].J Gastroentreol Hepatol , 2006,21(5):814-8.
[16] Maggioni M ,Coggi G, Cassani B , et al. Molecular changes in hepatocellular dysplastic nodules on microdissected liver biopsies [J].Hepatology , 2000, 32 (5): 942 - 946.
[17] Guang-Neng Zhu, Li Zuo, Qing Zhou, et al.Loss of heterozygosity on chromosome 10q22-10q23 and 22q11.2-22q12.1 and p53 gene in primary hepatocellular carcinoma[J]. World J Gastroenterol, 2004,10(13):1975-1978.
[18] Tomoe Lu, Hiroshi Hano, Chenxi Meng ,et al. Frequent loss of heterozygosity in two distinct regions , 8p23.1 and 8p22, in hepatocellular carcinoma[J]. World J Gastroenterol, 2007,13 (7):1090-1097.
[19] Wani K,Nair CK. Genetic alterations in cervical cancer[J]. Indian J Exp Biol,2003, 41(8):789-96.
[20] Chung TK, Cheung TH, Lo WK, et al.Loss of heterozygosity at the short arm of chromosome 3 in microdissected cervical intraepithelial neoplasia[J]. CancerLett, 2000,154 (2): 189-94.
[21] Kanianaviroikul N, Kohu K, Sato M, et al. Candidate regions of tumor suppressor gene by loss of heterozygosity analysis on chromosome 8pll. l-ql3. 3 in gastric cancer[J]. Cancer Lett, 2004,213(1):111-6.
[22] Caldes T, Perez-Sequra P, Torar A, et al. Microsatellite instability correlates with negative expression of estrogen and progesterone receptors in sporadic breast cancer[J]. Teratog Carcinog Mutagen, 2000,20(5):283-91.
[23] Nowacka-Zawisza M,Brys M, Hanna RM,et al .Loss of heterozygosity and microsatellite instability at RAD52 and RAD54 loci in breast cancer[J].Pol J Pathol, 2006;57 (2):83-9.
[24] Wistuba, II.Behrens C, Virmani AK:High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints[J]. Cancer Res, 2000,60:1949-1960.
[25] Eva FORGACS, Sabine ZOCHBAUER-MOLLER, Edit OLAH, et al. Molecular Genetic Abnormalities in the Pathogenesis of Human Lung Cancer[J]. Pathology oncology research, 2001,7 (1): 7-13.
[26] Takeuchi T, Minami Y, Iijima T, et al. Characteristics of loss of heterozygosity in large cell neuroendocrine carcinomas of the lung and small cell lung carcinomas[J]. Pathol Int,2006 56(8):434-9.
[27] Ninomiva H, Nomura K, Satoh Y, et al. Genetic instability in lung cancer: concurrent analysis of chromosomal,mini-and microsatellite instability and loss of heterozygosity[J].Br J Cancer, 2006, 94(10):1485-91.